Lataa...
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Idelalisib (Zydelig(™), also known as CAL-101 and GS-1101) was approved in 2014 in the United States and European Union for the treatment of three indolent B-cell neoplasms: relapsed/refractory chronic lymphocytic leukemia (CLL, in combination with rituximab), relapsed follicular lymphoma, and relap...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4523214/ https://ncbi.nlm.nih.gov/pubmed/25670221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2034 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|